Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies
Columbia, MD – June 5, 2019 – MedTech Breakthrough, an independent organization that recognizes the top companies and solutions in the global health and medical technology market, today announced that it has selected Welldoc’s BlueStar® platform, digital therapeutic for people with type 2 diabetes, as the winner of its “Best Personal Health App” award in the 2019 MedTech Breakthrough Awards program.
Welldoc’s BlueStar is an FDA-cleared digital therapeutic for individuals with type 2 diabetes, available on the web and as a mobile application, providing real-time feedback messages to help users become more knowledgeable about their health. The app includes seamless integrations with activity trackers, meters, and other devices to give users a full picture of their health, shareable with their care team.
“A glaringly positive theme that stood out during our 2019 MedTech Breakthrough Award evaluation process was companies dedicated to simplifying the gathering, evaluation and use of medical data to make better health decisions,” said James Johnson, managing director, MedTech Breakthrough. “Welldoc is a clear leader in this area with its BlueStar solution delivering personalized, real-time feedback and diabetes educational tools that are actionable and individualized. We extend a sincere congratulations to the Welldoc team members on their innovation and success with the BlueStar platform.”
The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Robotics, Clinical Administration, Telehealth, Patient Engagement, Electronic Health Records (EHR), mHealth, Medical Devices, Medical Data and many more. This year’s program attracted more than 3,500 nominations from over 15 different countries throughout the world.
“We are committed to guiding individuals through the complicated journey of living with chronic diseases through our digital therapeutic solutions and we are honored to receive significant industry recognition through the 2019 MedTech Breakthrough Award,” said Welldoc President and CEO Kevin McRaith. “I consider this designation a validation of our team’s focus and dedication to driving innovation in digital health, and we look forward to continuing to deliver on our mission of digital health innovation.”
Welldoc has developed more than 40 peer-reviewed publications and presentations on BlueStar, including two randomized, controlled clinical trials. Additionally, BlueStar delivers an estimated average cost savings of $254-$271 per user per month, proven clinical outcomes and a net promoter member satisfaction score of 70.
About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is an independent program devoted to honoring excellence in medical and health related technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough health and medical companies and products in categories that include Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.
Welldoc® is a leading digital therapeutic company revolutionizing chronic disease management to help transform lives. The Company’s groundbreaking technology helps guide individuals through the complicated journey of living with chronic diseases, with a goal of helping them self-manage their conditions, while connecting them to their own healthcare team. By utilizing Welldoc’s digital therapeutic solutions, payers, employers and healthcare systems can streamline their resources by focusing on a digital health solution to help better manage their populations living with multiple and costly chronic diseases. Welldoc is based on a life science business model—having conducted multiple randomized clinical trials resulting in more than 40 peer-reviewed publications. IBM Watson Health™ conducted an innovative economic analysis for Welldoc using the MarketScan® Commercial Claims and Encounters Database and the MarketScan® Medicare Supplemental and Coordination of Benefits Database demonstrating an opportunity to save a range of $254 to $271 per user per month with the use of the flagship BlueStar® digital therapeutic. Welldoc has a solid foundation in the development of solutions for the management of diabetes and is rapidly creating other chronic disease solutions. This year, Welldoc secured a patent for the Software Engine Technology that powers BlueStar. Notably, this is the Company’s tenth issued patent. For more information, visit www.welldoc.com.